Last reviewed · How we verify
NCT06282484
A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions
trial in Gastric Xanthoma in 1,260 participants. Completed in 29 September 2023.
1 June 2023
Quick facts
| Lead sponsor | Xijing Hospital of Digestive Diseases |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,260 |
| Start date | 1 September 2022 |
| Primary completion | 1 June 2023 |
| Estimated completion | 29 September 2023 |
| Sites | 1 location across China |
Conditions studied
- Gastric Xanthoma — all drugs for Gastric Xanthoma →
- Helicobacter Pylori Infection — all drugs for Helicobacter Pylori Infection →
- Gastric Cancer — all drugs for Gastric Cancer →
- Intestinal Metaplasia — all drugs for Intestinal Metaplasia →
Sponsor
Xijing Hospital of Digestive Diseases
Who can join
Adults 18 to 75, any sex, with Gastric Xanthoma or Helicobacter Pylori Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.
Gao MJ, Li SB, Zhu XJ, Zhang LF, et al · · 2024 · cited 2× · PMID 39865979 · DOI 10.1111/1751-2980.13326
Verify or expand the search:
- PubMed search for NCT06282484
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xijing Hospital of Digestive Diseases trials
Trials by the same sponsor.
- NCT07401303 — Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time · NA · not yet recruiting
- NCT07296458 — FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy · Phase 3 · recruiting
- NCT07129460 — Efficacy and Safety of Berberine for Gastric Intestinal Metaplasia · Phase 4 · not yet recruiting
- NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06282484 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital of Digestive Diseases
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06282484.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing